Download the full report (112 p.) - KCE

94 Interventions in Alzheimer’s Disease KCE Reports 111
83. Ballard C, Waite J, Birks J. The effectiveness of atypical antipsychotics for the treatment of
aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev.
84.
2006(1):CD003476.
Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine
on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann
Pharmacother. 2008;42(1):32-8.
85. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series
study. BMJ. 2008;337:a1227.
86. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of
dementia: a review of the evidence. JAMA. 2005;293(5):596-608.
87. Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of
risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a metaanalysis
of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22(5):475-84.
88. Clegg A, Bryant J, Nicholson T, McIntyre L, De BS, Gerard K, et al. Clinical and costeffectiveness
of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and
systematic review. Systematic review. The National Coordinating Centre for Health
Technology Assessment (NCCHTA) on behalf of Southampton Health Technology
Assessments Centre(SHTAC) Southampton.; 2001. Available from:
89.
http://www.hta.ac.uk/execsumm/summ501.htm
Shukla VK, Otten N. Drug treatments for Alzheimer's disease. III. A review of
pharmacoeconomic evaluations. Systematic review. Canadian Coordinating Office for Health
Technology Assessment (CCOHTA); 2000. Technology Report Issue 11 Available from:
https://www.ccohta.ca/
90. Knowles J. Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical
and economic outcomes. Core Evidence. 2006;1(3):195-219.
91. Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of
memantine in community-based Alzheimer's disease patients: An adaptation in Spain.[see
comment]. Eur J Health Econ. 2006;7(2):137-44.
92. Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Assessing the health and
economic impact of galantamine treatment in patients with Alzheimer's disease in the health
care systems of different countries. Drugs & Aging. 2004;21(10):677-86.
93. Fagnani F, Lafuma A, Pechevis M, Rigaud AS, Traykov L, Seux ML, et al. Donepezil for the
treatment of mild to moderate Alzheimer's disease in France: the economic implications.
Dementia & Geriatric Cognitive Disorders. 2004;17(1-2):5-13.
94. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation of
donepezil in moderate to severe Alzheimer disease.[see comment]. Neurology.
95.
2004;63(4):644-50.
Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately
severe to severe Alzheimer's disease: A Markov model in Finland. Clinical Drug Investigation.
2004;24(7):373-84.
96. Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's
disease in Taiwan. International Journal of Geriatric Psychiatry. 2008;23(1):73-8.
97. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with
standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry.
2007;52(8):519-26.
98. Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling the cost effectiveness of
cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's
disease.[see comment]. Pharmacoeconomics. 2005;23(12):1271-82.
99. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease:
an analysis based on a probabilistic Markov model from a UK perspective. Drugs & Aging.
2004;21(9):607-20.
100. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in
Sweden. Am J Geriatr Pharmacother. 2005;3(2):77-86.
101. Martikainen J, Valtonen H, Pirttila T. Potential cost-effectiveness of a family-based program in
mild Alzheimer's disease patients. Eur J Health Econ. 2004;5(2):136-42.